Copyright
©The Author(s) 2022.
World J Clin Cases. Apr 6, 2022; 10(10): 3101-3112
Published online Apr 6, 2022. doi: 10.12998/wjcc.v10.i10.3101
Published online Apr 6, 2022. doi: 10.12998/wjcc.v10.i10.3101
Age of patients | yr |
Median | 63 |
Mean | 60.6 |
Minimum | 32 |
Maximum | 82 |
Level of education | |
Primary education | 21% |
Upper secondary education | 53% |
Master/doctoral education | 26% |
Gender | |
Male | 56.4% |
Female | 43.6% |
Initial stage | |
Stage II high risk | 3.9% |
Stage III | 34.7% |
Stage IV | 61.4% |
Purpose of treatment | |
Curative | 41.6% |
Palliative | 56.4% |
Undefined | 2.0% |
Karnofsky performance status | |
100% | 5.9% |
90% | 45.5% |
80% | 36.5% |
70% | 6.9% |
60% | 5% |
Chemotherapy | |
FOLFOX | 37.4% |
CapeOX | 45.5% |
Other | 17.1% |
Relevant comorbidities | |
None | 55.2% |
Diabetes mellitus | 10.3% |
Alcohol abuse | 3.3% |
Cardio-vascular diseases | 20.1% |
Other | 11.1% |
Diabetes-insulin treatment | |
Yes | 8.4% |
No | 91.6% |
- Citation: Prutianu I, Alexa-Stratulat T, Cristea EO, Nicolau A, Moisuc DC, Covrig AA, Ivanov K, Croitoru AE, Miron MI, Dinu MI, Ivanov AV, Marinca MV, Radu I, Gafton B. Oxaliplatin-induced neuropathy and colo-rectal cancer patient’s quality of life: Practical lessons from a prospective cross-sectional, real-world study. World J Clin Cases 2022; 10(10): 3101-3112
- URL: https://www.wjgnet.com/2307-8960/full/v10/i10/3101.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i10.3101